Baxter International Inc. vs Johnson & Johnson — Stock Comparison
Baxter International Inc. (BAX) and Johnson & Johnson (JNJ) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Johnson & Johnson scores ahead of Baxter International Inc. on Q·Score (6.6 vs 5.2 out of 10), led by Quality (8.5 vs 4) and Sentiment (7.4 vs 3.5). Baxter International Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for BAX (+20.7%) than for JNJ (+2.3%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $27.75 is 21% above current price.
⚠ cautious analyst consensus — few Buy ratings.
High-quality business with 20% return on equity and 16% profit margins.
⚠ earnings contracting 96% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
BAX vs JNJ: which stock scores better overall?
Based on Q·Score, Johnson & Johnson (JNJ) scores 6.6/10 versus Baxter International Inc. (BAX) at 5.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: BAX or JNJ?
Baxter International Inc. (BAX) scores higher on Growth (5.9/10 vs 4.3/10). Baxter International Inc. reports revenue growth (5.0% YoY) while Johnson & Johnson reports (5.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is BAX or JNJ more attractively valued?
Baxter International Inc. (BAX) scores higher on Valuation (7.5/10 vs 5.8/10). BAX trades at 11.2× P/E versus JNJ at 23.5×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about BAX vs JNJ?
There are 12 analysts covering BAX with a consensus price target of $27.75, and 22 analysts covering JNJ with a consensus target of $279.41. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: BAX or JNJ?
Johnson & Johnson (JNJ) scores higher on Quality (8.5/10 vs 4/10). Net profit margin: BAX at -6.2%, JNJ at 16.2%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: BAX or JNJ?
Johnson & Johnson (JNJ) scores higher on Financial Health (6.5/10 vs 5/10). Market beta: BAX at N/A, JNJ at 0.21. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of BAX and JNJ?
Baxter International Inc. (BAX) has a market capitalisation of $11.9B, while Johnson & Johnson (JNJ) has a market cap of $657.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do BAX or JNJ pay dividends?
BAX pays a dividend yield of 0.17%, while JNJ pays a dividend yield of 1.95%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →